Fragment-Based Drug Discovery: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 1: Line 1:
== Paclitaxel in Apoptosis ==
== Rasagiline Analogues in Monoamine Oxidase Inhibition ==
<StructureSection load='1ysi' size='350' side='right' caption='Structure of HMG-CoA reductase (PDB entry [[1ysi]])' scene=''>
<StructureSection load='2c64' size='350' side='right' caption='Structure of HMG-CoA reductase (PDB entry [[2c64]])' scene=''>
This represents the inhibition of the anti-apoptotic protein, Bcl-xl, by and anti-cancer drug, paclitaxel.
This represents the irreversible and selective inhibition of MAO-B by rasagiline.


</StructureSection>
</StructureSection>

Revision as of 22:15, 17 September 2012

Rasagiline Analogues in Monoamine Oxidase InhibitionRasagiline Analogues in Monoamine Oxidase Inhibition

This represents the irreversible and selective inhibition of MAO-B by rasagiline.


Structure of HMG-CoA reductase (PDB entry 2c64)

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Arthur Cox, Justin Weekley, Jaime Prilusky
Retrieved from "https://proteopedia.openfox.io/wiki/index.php?title=Fragment-Based_Drug_Discovery&oldid=1534469"